#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating cancer survivors need to understand that their patients may have significantly different perceptions of cannabis risks than medical evidence supports, which can lead to miscommunication about safety and efficacy. This gap in risk awareness between providers and patients highlights the need for standardized counseling approaches and updated clinical guidelines to ensure informed decision-making about cannabis use in the survivorship population. Improved provider-patient dialogue about cannabis is essential given the prevalence of use among cancer survivors and the limited evidence base for its therapeutic benefits in cancer care.
This study reveals a significant gap between cancer survivors’ and healthcare providers’ perceptions regarding cannabis safety and risk, with survivors and providers showing divergent levels of awareness about potential cannabis-related harms and benefits. The findings indicate that many cancer patients may be using cannabis without adequate counseling about risks, while providers may underestimate patient interest in or use of cannabis products for symptom management. This communication disconnect has important implications for oncology practice, as survivors increasingly turn to cannabis for pain, nausea, and anxiety management without clear guidance from their care teams. The research underscores the need for standardized, evidence-based cannabis counseling protocols integrated into cancer care to ensure patients have accurate risk-benefit information when considering cannabis use. Clinicians managing cancer survivors should proactively initiate cannabis discussions, assess current or contemplated use, and provide evidence-based information about efficacy and safety in the oncology context rather than assuming patients will volunteer this information.
“What this survey tells us is that we have a significant communication gap between what oncologists and cancer survivors understand about cannabis risks, and that’s worth taking seriously in clinical practice; we need better, evidence-based conversations with our patients rather than assuming either side has complete information.”
💊 Divergent risk perception between cancer survivors and their healthcare providers regarding cannabis presents a significant communication gap with potential clinical consequences. Survivors may underestimate cannabis-related harms or overestimate therapeutic benefits, particularly given limited high-quality evidence for cannabis in cancer symptom management and the lack of standardized dosing or quality control in most jurisdictions. Providers, conversely, may lack training in cannabis pharmacology and cannabinoid interactions with chemotherapy or supportive care medications, creating mutual uncertainty that inhibits productive dialogue. Rather than avoiding the discussion, clinicians caring for cancer patients should proactively assess cannabis use and intentions, acknowledge the evidence gaps honestly, and discuss documented risks including potential drug interactions, cognitive effects, and cannabis use disorder in vulnerable populations. Establishing shared decision-making frameworks and staying informed about evolving clinical evidence will help providers guide survivors toward evidence-based symptom management while respecting their autonomy and maintaining trust.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
